Gravar-mail: Correction to “A Novel Aminotetralin-Type Serotonin (5-HT) (2C) Receptor-Specific Agonist and 5-HT(2A) Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses”